IGC — IGC Pharma, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1326205 ·
Last close
$0.29
Market Cap
$28.55M
52W High
$0.36
52W Low
$0.25
ADV30
2,006,801
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 317,000 | 55,000 | -2,458,000 | -2,402,000 | 9,185,000 | 207,000 | 3,064,000 |
| Dec 2025 | 350,000 | 44,000 | -2,941,000 | -726,000 | 9,712,000 | 900,000 | 2,289,000 |
| Sep 2025 | 191,000 | 99,000 | -2,899,000 | -1,821,000 | 9,743,000 | 1,105,000 | 1,651,000 |
| Jun 2025 | 328,000 | 154,000 | -1,905,000 | -1,599,000 | 7,943,000 | 454,000 | 1,865,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,450,000
Investing CF
$-164,000
Financing CF
$6,030,000
CapEx
$-819,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.08
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-124,890,000
Inventory
$640,000
Receivables
$75,000
ST Investments
$38,000
EBIT TTM
$-9,157,000
Pretax Income TTM
$-5,343,000
Interest Exp TTM
—
Analysts
2
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,106,000
EBITDA
$-7,524,000
Free Cash Flow
$-2,521,375
Enterprise Value
$29,508,300
Total Cash
$235,000
Total Debt
$917,000
Shares Out
100,091,317
Trailing EPS
$-0.06
Book Value
$0.06
ROE
-83.3%
ROA
-50.3%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2025 | 1,271,000 | -7,446,000 | -7,121,000 | 8,747,000 | 2,417,000 | — | -4,065,000 |
| Mar 2024 | 1,345,000 | -9,798,000 | -13,000,000 | 9,902,000 | 2,581,000 | — | -5,199,000 |
| Mar 2023 | 911,000 | -11,571,000 | -11,506,000 | 17,178,000 | 2,267,000 | — | -7,047,000 |
| Mar 2022 | 397,000 | -15,428,000 | -15,016,000 | 26,834,000 | 2,942,000 | — | -7,462,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.09
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GRDX | GridAI Technologies Corp. | $28.58M | $4.61 | — |
| SER | Serina Therapeutics, Inc. | $28.80M | $1.92 | — |
| CRVO | CervoMed Inc. | $28.24M | $3.05 | — |
| SKYE | Skye Bioscience, Inc. | $28.89M | $0.82 | — |
| PVCT | PROVECTUS BIOPHARMACEUTICALS, INC. | $28.96M | $0.07 | — |
News headlines (Yahoo Finance, 1h cache)
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment
2026-05-19 21:30 · Yahoo
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference
2026-05-15 12:00 · Yahoo
IGC Pharma Advances Caregiver Engagement as Phase 2 CALMA Trial Advances Final Enrollment Phase
2026-04-28 16:15 · Yahoo
New to The Street Broadcasts Show #746 Tonight on Bloomberg Television 6:30PM EST Featuring NRx Pharma (NASDAQ:NRXP), Performance Golf, Lost Soldier Oil & Gas, Dr. Lee Gause, and CISO Global
2026-04-25 16:55 · Yahoo
IGC Pharma Adds Kerwin Medical Center in Dallas to Phase 2 CALMA Trial as Enrollment Advances Toward Completion
2026-04-22 12:30 · Yahoo
IGC Pharma Secures Psilocybin Research Authorization, Expanding Focus on Neuropsychiatric Symptoms in Dementia
2026-04-20 12:30 · Yahoo
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Gro
2026-04-18 14:00 · Yahoo
IGC Pharma Reaches 80% Enrollment in Phase 2 CALMA Trial, Entering Final Phase Ahead of Enrollment Completion and Data Readout
2026-04-14 12:30 · Yahoo
New to The Street Broadcasts on Bloomberg Television at 6:30 PM EST Featuring IGC Pharma (IGC), Vivos Therapeutics (VVOS), Acurx Pharmaceuticals (ACXP), and Equinox Gold (EQX)
2026-04-11 13:35 · Yahoo
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.25, Citing Clinical Progress and Upcoming Catalysts
2026-04-08 16:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.